nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—breast cancer—bone cancer	0.63	1	CtDrD
Raloxifene—CYP3A4—bone cancer	0.193	1	CbGaD
Raloxifene—AOX1—Methotrexate—bone cancer	0.063	0.643	CbGbCtD
Raloxifene—CYP2B6—Cisplatin—bone cancer	0.0186	0.19	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—bone cancer	0.0125	0.127	CbGbCtD
Raloxifene—Coronary heart disease—Cisplatin—bone cancer	0.00656	0.134	CcSEcCtD
Raloxifene—CYP3A4—Doxorubicin—bone cancer	0.00384	0.0392	CbGbCtD
Raloxifene—Retinal vein thrombosis—Methotrexate—bone cancer	0.00247	0.0503	CcSEcCtD
Raloxifene—Coronary artery disease—Cisplatin—bone cancer	0.0012	0.0243	CcSEcCtD
Raloxifene—Thromboembolic event—Methotrexate—bone cancer	0.000962	0.0196	CcSEcCtD
Raloxifene—Venous thromboembolism—Epirubicin—bone cancer	0.000825	0.0168	CcSEcCtD
Raloxifene—Venous thromboembolism—Doxorubicin—bone cancer	0.000764	0.0155	CcSEcCtD
Raloxifene—Infection—Carboplatin—bone cancer	0.000571	0.0116	CcSEcCtD
Raloxifene—Tenderness—Cisplatin—bone cancer	0.000541	0.011	CcSEcCtD
Raloxifene—Leukorrhea—Epirubicin—bone cancer	0.000517	0.0105	CcSEcCtD
Raloxifene—Pain—Carboplatin—bone cancer	0.000491	0.01	CcSEcCtD
Raloxifene—Embolism venous—Epirubicin—bone cancer	0.000481	0.00979	CcSEcCtD
Raloxifene—Leukorrhea—Doxorubicin—bone cancer	0.000479	0.00975	CcSEcCtD
Raloxifene—Body temperature increased—Carboplatin—bone cancer	0.000454	0.00925	CcSEcCtD
Raloxifene—Embolism venous—Doxorubicin—bone cancer	0.000445	0.00906	CcSEcCtD
Raloxifene—Deep vein thrombosis—Methotrexate—bone cancer	0.000426	0.00868	CcSEcCtD
Raloxifene—Vaginal discharge—Methotrexate—bone cancer	0.000426	0.00868	CcSEcCtD
Raloxifene—Embolism—Methotrexate—bone cancer	0.000404	0.00822	CcSEcCtD
Raloxifene—Vaginal discharge—Epirubicin—bone cancer	0.000399	0.00812	CcSEcCtD
Raloxifene—Embolism—Epirubicin—bone cancer	0.000378	0.00769	CcSEcCtD
Raloxifene—Vaginal discharge—Doxorubicin—bone cancer	0.000369	0.00751	CcSEcCtD
Raloxifene—Cerebrovascular accident—Cisplatin—bone cancer	0.00035	0.00712	CcSEcCtD
Raloxifene—Embolism—Doxorubicin—bone cancer	0.00035	0.00712	CcSEcCtD
Raloxifene—Neuralgia—Epirubicin—bone cancer	0.000349	0.00711	CcSEcCtD
Raloxifene—Laryngitis—Epirubicin—bone cancer	0.000337	0.00685	CcSEcCtD
Raloxifene—Vaginal haemorrhage—Epirubicin—bone cancer	0.000328	0.00667	CcSEcCtD
Raloxifene—Neuralgia—Doxorubicin—bone cancer	0.000323	0.00658	CcSEcCtD
Raloxifene—Laryngitis—Doxorubicin—bone cancer	0.000311	0.00634	CcSEcCtD
Raloxifene—Breast disorder—Cisplatin—bone cancer	0.00031	0.00631	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000309	0.00629	CcSEcCtD
Raloxifene—Vaginal haemorrhage—Doxorubicin—bone cancer	0.000303	0.00617	CcSEcCtD
Raloxifene—Neoplasm malignant—Epirubicin—bone cancer	0.000284	0.00578	CcSEcCtD
Raloxifene—Breast pain—Epirubicin—bone cancer	0.000278	0.00566	CcSEcCtD
Raloxifene—Vasodilation procedure—Epirubicin—bone cancer	0.000276	0.00562	CcSEcCtD
Raloxifene—Vasodilation—Epirubicin—bone cancer	0.000276	0.00562	CcSEcCtD
Raloxifene—Cough increased—Epirubicin—bone cancer	0.000265	0.0054	CcSEcCtD
Raloxifene—Neoplasm malignant—Doxorubicin—bone cancer	0.000263	0.00535	CcSEcCtD
Raloxifene—Pulmonary embolism—Methotrexate—bone cancer	0.000259	0.00528	CcSEcCtD
Raloxifene—Vaginal inflammation—Methotrexate—bone cancer	0.000259	0.00528	CcSEcCtD
Raloxifene—Breast pain—Doxorubicin—bone cancer	0.000257	0.00524	CcSEcCtD
Raloxifene—Conjunctivitis—Cisplatin—bone cancer	0.000257	0.00523	CcSEcCtD
Raloxifene—Vasodilation procedure—Doxorubicin—bone cancer	0.000255	0.0052	CcSEcCtD
Raloxifene—Vasodilation—Doxorubicin—bone cancer	0.000255	0.0052	CcSEcCtD
Raloxifene—Cystitis noninfective—Methotrexate—bone cancer	0.000253	0.00516	CcSEcCtD
Raloxifene—Cystitis—Methotrexate—bone cancer	0.00025	0.0051	CcSEcCtD
Raloxifene—Cough increased—Doxorubicin—bone cancer	0.000245	0.00499	CcSEcCtD
Raloxifene—Vaginal infection—Methotrexate—bone cancer	0.000245	0.00498	CcSEcCtD
Raloxifene—Vaginal inflammation—Epirubicin—bone cancer	0.000243	0.00494	CcSEcCtD
Raloxifene—Pulmonary embolism—Epirubicin—bone cancer	0.000243	0.00494	CcSEcCtD
Raloxifene—Cystitis noninfective—Epirubicin—bone cancer	0.000237	0.00482	CcSEcCtD
Raloxifene—Bladder pain—Methotrexate—bone cancer	0.000234	0.00477	CcSEcCtD
Raloxifene—Urinary tract disorder—Cisplatin—bone cancer	0.000234	0.00477	CcSEcCtD
Raloxifene—Cystitis—Epirubicin—bone cancer	0.000234	0.00477	CcSEcCtD
Raloxifene—Connective tissue disorder—Cisplatin—bone cancer	0.000233	0.00475	CcSEcCtD
Raloxifene—Urethral disorder—Cisplatin—bone cancer	0.000233	0.00473	CcSEcCtD
Raloxifene—Vaginal infection—Epirubicin—bone cancer	0.000229	0.00466	CcSEcCtD
Raloxifene—Pulmonary embolism—Doxorubicin—bone cancer	0.000224	0.00457	CcSEcCtD
Raloxifene—Vaginal inflammation—Doxorubicin—bone cancer	0.000224	0.00457	CcSEcCtD
Raloxifene—Cramps of lower extremities—Epirubicin—bone cancer	0.000223	0.00454	CcSEcCtD
Raloxifene—Cardiac disorder—Cisplatin—bone cancer	0.00022	0.00448	CcSEcCtD
Raloxifene—Flushing—Cisplatin—bone cancer	0.00022	0.00448	CcSEcCtD
Raloxifene—Bladder pain—Epirubicin—bone cancer	0.000219	0.00447	CcSEcCtD
Raloxifene—Cystitis noninfective—Doxorubicin—bone cancer	0.000219	0.00446	CcSEcCtD
Raloxifene—Cystitis—Doxorubicin—bone cancer	0.000217	0.00441	CcSEcCtD
Raloxifene—Diabetes mellitus—Methotrexate—bone cancer	0.000216	0.0044	CcSEcCtD
Raloxifene—Vaginal infection—Doxorubicin—bone cancer	0.000212	0.00431	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—bone cancer	0.000206	0.0042	CcSEcCtD
Raloxifene—Flatulence—Cisplatin—bone cancer	0.000203	0.00414	CcSEcCtD
Raloxifene—Bladder pain—Doxorubicin—bone cancer	0.000203	0.00413	CcSEcCtD
Raloxifene—Diabetes mellitus—Epirubicin—bone cancer	0.000202	0.00412	CcSEcCtD
Raloxifene—Muscle spasms—Cisplatin—bone cancer	0.000199	0.00404	CcSEcCtD
Raloxifene—Cerebrovascular accident—Methotrexate—bone cancer	0.000192	0.00391	CcSEcCtD
Raloxifene—Hot flush—Epirubicin—bone cancer	0.000188	0.00383	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—bone cancer	0.000187	0.00381	CcSEcCtD
Raloxifene—Menopausal symptoms—Epirubicin—bone cancer	0.000187	0.0038	CcSEcCtD
Raloxifene—Cerebrovascular accident—Epirubicin—bone cancer	0.00018	0.00366	CcSEcCtD
Raloxifene—Myalgia—Cisplatin—bone cancer	0.000176	0.00358	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000175	0.00356	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—bone cancer	0.000174	0.00355	CcSEcCtD
Raloxifene—Migraine—Epirubicin—bone cancer	0.000173	0.00353	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—bone cancer	0.000173	0.00352	CcSEcCtD
Raloxifene—Breast disorder—Methotrexate—bone cancer	0.00017	0.00346	CcSEcCtD
Raloxifene—Infection—Cisplatin—bone cancer	0.000167	0.00341	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—bone cancer	0.000166	0.00339	CcSEcCtD
Raloxifene—Nervous system disorder—Cisplatin—bone cancer	0.000165	0.00337	CcSEcCtD
Raloxifene—Thrombocytopenia—Cisplatin—bone cancer	0.000165	0.00336	CcSEcCtD
Raloxifene—Skin disorder—Cisplatin—bone cancer	0.000164	0.00333	CcSEcCtD
Raloxifene—Hyperhidrosis—Cisplatin—bone cancer	0.000163	0.00332	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—bone cancer	0.00016	0.00327	CcSEcCtD
Raloxifene—Breast disorder—Epirubicin—bone cancer	0.000159	0.00324	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000159	0.00323	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000154	0.00313	CcSEcCtD
Raloxifene—Influenza—Epirubicin—bone cancer	0.000152	0.0031	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—bone cancer	0.000147	0.003	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000147	0.00299	CcSEcCtD
Raloxifene—Bronchitis—Epirubicin—bone cancer	0.000146	0.00298	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—bone cancer	0.000146	0.00297	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Cisplatin—bone cancer	0.000146	0.00296	CcSEcCtD
Raloxifene—Depression—Methotrexate—bone cancer	0.000145	0.00294	CcSEcCtD
Raloxifene—Pain—Cisplatin—bone cancer	0.000144	0.00293	CcSEcCtD
Raloxifene—Conjunctivitis—Methotrexate—bone cancer	0.000141	0.00287	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—bone cancer	0.000141	0.00287	CcSEcCtD
Raloxifene—Sweating—Methotrexate—bone cancer	0.000139	0.00283	CcSEcCtD
Raloxifene—Weight increased—Epirubicin—bone cancer	0.000139	0.00282	CcSEcCtD
Raloxifene—Pneumonia—Epirubicin—bone cancer	0.000136	0.00278	CcSEcCtD
Raloxifene—HTR2B—G alpha (q) signalling events—GRM1—bone cancer	0.000136	0.00464	CbGpPWpGaD
Raloxifene—ESR1—FOXM1 transcription factor network—CDK4—bone cancer	0.000136	0.00462	CbGpPWpGaD
Raloxifene—Bronchitis—Doxorubicin—bone cancer	0.000135	0.00276	CcSEcCtD
Raloxifene—Body temperature increased—Cisplatin—bone cancer	0.000133	0.00271	CcSEcCtD
Raloxifene—Conjunctivitis—Epirubicin—bone cancer	0.000132	0.00269	CcSEcCtD
Raloxifene—Urinary tract infection—Epirubicin—bone cancer	0.000132	0.00269	CcSEcCtD
Raloxifene—Sweating—Epirubicin—bone cancer	0.00013	0.00265	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—bone cancer	0.000129	0.00263	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000129	0.0044	CbGpPWpGaD
Raloxifene—Urinary tract disorder—Methotrexate—bone cancer	0.000129	0.00262	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—bone cancer	0.000128	0.00261	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—bone cancer	0.000128	0.0026	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000127	0.00434	CbGpPWpGaD
Raloxifene—Sinusitis—Epirubicin—bone cancer	0.000127	0.00259	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—bone cancer	0.000126	0.00257	CcSEcCtD
Raloxifene—ESR2—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000124	0.00422	CbGpPWpGaD
Raloxifene—Rhinitis—Epirubicin—bone cancer	0.000122	0.00249	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—bone cancer	0.000122	0.00249	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—bone cancer	0.000122	0.00249	CcSEcCtD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000122	0.00415	CbGpPWpGaD
Raloxifene—Hypoaesthesia—Epirubicin—bone cancer	0.000121	0.00247	CcSEcCtD
Raloxifene—Pharyngitis—Epirubicin—bone cancer	0.000121	0.00246	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—bone cancer	0.000121	0.00246	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—bone cancer	0.00012	0.00245	CcSEcCtD
Raloxifene—Urinary tract disorder—Epirubicin—bone cancer	0.00012	0.00245	CcSEcCtD
Raloxifene—Oedema peripheral—Epirubicin—bone cancer	0.00012	0.00244	CcSEcCtD
Raloxifene—Connective tissue disorder—Epirubicin—bone cancer	0.00012	0.00244	CcSEcCtD
Raloxifene—Urethral disorder—Epirubicin—bone cancer	0.000119	0.00243	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—bone cancer	0.000118	0.0024	CcSEcCtD
Raloxifene—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000118	0.00402	CbGpPWpGaD
Raloxifene—ESR1—FOXM1 transcription factor network—RB1—bone cancer	0.000118	0.00402	CbGpPWpGaD
Raloxifene—Sinusitis—Doxorubicin—bone cancer	0.000118	0.0024	CcSEcCtD
Raloxifene—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.000117	0.00398	CbGpPWpGaD
Raloxifene—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000116	0.00397	CbGpPWpGaD
Raloxifene—Diarrhoea—Cisplatin—bone cancer	0.000115	0.00235	CcSEcCtD
Raloxifene—ESR1—Plasma membrane estrogen receptor signaling—MMP2—bone cancer	0.000115	0.00393	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000115	0.00392	CbGpPWpGaD
Raloxifene—ESR1—FOXM1 transcription factor network—MMP2—bone cancer	0.000113	0.00385	CbGpPWpGaD
Raloxifene—Cardiac disorder—Epirubicin—bone cancer	0.000113	0.0023	CcSEcCtD
Raloxifene—Flushing—Epirubicin—bone cancer	0.000113	0.0023	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—bone cancer	0.000113	0.0023	CcSEcCtD
Raloxifene—Hypoaesthesia—Doxorubicin—bone cancer	0.000112	0.00228	CcSEcCtD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000112	0.00382	CbGpPWpGaD
Raloxifene—Pharyngitis—Doxorubicin—bone cancer	0.000112	0.00228	CcSEcCtD
Raloxifene—Urinary tract disorder—Doxorubicin—bone cancer	0.000111	0.00227	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—bone cancer	0.000111	0.00226	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—bone cancer	0.000111	0.00226	CcSEcCtD
Raloxifene—Angiopathy—Epirubicin—bone cancer	0.000111	0.00225	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—bone cancer	0.00011	0.00225	CcSEcCtD
Raloxifene—ESR2—Generic Transcription Pathway—NR1I2—bone cancer	0.00011	0.00374	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00011	0.00374	CbGpPWpGaD
Raloxifene—ESR1—ATF-2 transcription factor network—PLAU—bone cancer	0.000109	0.00372	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000108	0.00368	CbGpPWpGaD
Raloxifene—Vomiting—Cisplatin—bone cancer	0.000107	0.00218	CcSEcCtD
Raloxifene—Rash—Cisplatin—bone cancer	0.000106	0.00216	CcSEcCtD
Raloxifene—Dermatitis—Cisplatin—bone cancer	0.000106	0.00216	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—bone cancer	0.000105	0.00213	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—bone cancer	0.000105	0.00213	CcSEcCtD
Raloxifene—Flatulence—Epirubicin—bone cancer	0.000104	0.00213	CcSEcCtD
Raloxifene—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.000104	0.00356	CbGpPWpGaD
Raloxifene—ESR1—ATF-2 transcription factor network—CDK4—bone cancer	0.000103	0.00352	CbGpPWpGaD
Raloxifene—Angiopathy—Doxorubicin—bone cancer	0.000102	0.00208	CcSEcCtD
Raloxifene—Muscle spasms—Epirubicin—bone cancer	0.000102	0.00208	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—bone cancer	0.000102	0.00207	CcSEcCtD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000101	0.00344	CbGpPWpGaD
Raloxifene—Nausea—Cisplatin—bone cancer	0.0001	0.00204	CcSEcCtD
Raloxifene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	9.98e-05	0.0034	CbGpPWpGaD
Raloxifene—Cough—Methotrexate—bone cancer	9.89e-05	0.00201	CcSEcCtD
Raloxifene—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	9.85e-05	0.00336	CbGpPWpGaD
Raloxifene—Flatulence—Doxorubicin—bone cancer	9.67e-05	0.00197	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—bone cancer	9.65e-05	0.00196	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—bone cancer	9.65e-05	0.00196	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—bone cancer	9.65e-05	0.00196	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.58e-05	0.00195	CcSEcCtD
Raloxifene—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.56e-05	0.00326	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—PLAU—bone cancer	9.53e-05	0.00325	CbGpPWpGaD
Raloxifene—Vertigo—Epirubicin—bone cancer	9.53e-05	0.00194	CcSEcCtD
Raloxifene—Syncope—Epirubicin—bone cancer	9.51e-05	0.00194	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—bone cancer	9.43e-05	0.00192	CcSEcCtD
Raloxifene—Loss of consciousness—Epirubicin—bone cancer	9.32e-05	0.0019	CcSEcCtD
Raloxifene—Cough—Epirubicin—bone cancer	9.25e-05	0.00188	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	9.23e-05	0.00315	CbGpPWpGaD
Raloxifene—Infection—Methotrexate—bone cancer	9.19e-05	0.00187	CcSEcCtD
Raloxifene—AOX1—Metabolism—NDUFA12—bone cancer	9.17e-05	0.00312	CbGpPWpGaD
Raloxifene—Nervous system disorder—Methotrexate—bone cancer	9.07e-05	0.00185	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—bone cancer	9.06e-05	0.00184	CcSEcCtD
Raloxifene—Chest pain—Epirubicin—bone cancer	9.03e-05	0.00184	CcSEcCtD
Raloxifene—Arthralgia—Epirubicin—bone cancer	9.03e-05	0.00184	CcSEcCtD
Raloxifene—Myalgia—Epirubicin—bone cancer	9.03e-05	0.00184	CcSEcCtD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	9.01e-05	0.00307	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	9e-05	0.00307	CbGpPWpGaD
Raloxifene—Skin disorder—Methotrexate—bone cancer	8.98e-05	0.00183	CcSEcCtD
Raloxifene—ESR1—ATF-2 transcription factor network—RB1—bone cancer	8.98e-05	0.00306	CbGpPWpGaD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.97e-05	0.00183	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—bone cancer	8.94e-05	0.00182	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—bone cancer	8.82e-05	0.0018	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—bone cancer	8.8e-05	0.00179	CcSEcCtD
Raloxifene—HTR2B—G alpha (q) signalling events—GNA11—bone cancer	8.77e-05	0.00299	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—GRM4—bone cancer	8.67e-05	0.00295	CbGpPWpGaD
Raloxifene—ESR1—Plasma membrane estrogen receptor signaling—MMP9—bone cancer	8.66e-05	0.00295	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	8.66e-05	0.00295	CbGpPWpGaD
Raloxifene—Loss of consciousness—Doxorubicin—bone cancer	8.62e-05	0.00176	CcSEcCtD
Raloxifene—ESR1—ATF-2 transcription factor network—MMP2—bone cancer	8.62e-05	0.00294	CbGpPWpGaD
Raloxifene—Infection—Epirubicin—bone cancer	8.6e-05	0.00175	CcSEcCtD
Raloxifene—Cough—Doxorubicin—bone cancer	8.56e-05	0.00174	CcSEcCtD
Raloxifene—Shock—Epirubicin—bone cancer	8.52e-05	0.00173	CcSEcCtD
Raloxifene—Nervous system disorder—Epirubicin—bone cancer	8.49e-05	0.00173	CcSEcCtD
Raloxifene—Thrombocytopenia—Epirubicin—bone cancer	8.47e-05	0.00173	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—bone cancer	8.43e-05	0.00172	CcSEcCtD
Raloxifene—ESR1—FOXA1 transcription factor network—JUN—bone cancer	8.42e-05	0.00287	CbGpPWpGaD
Raloxifene—Skin disorder—Epirubicin—bone cancer	8.41e-05	0.00171	CcSEcCtD
Raloxifene—Hyperhidrosis—Epirubicin—bone cancer	8.37e-05	0.0017	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—bone cancer	8.36e-05	0.0017	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—bone cancer	8.35e-05	0.0017	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—bone cancer	8.35e-05	0.0017	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—bone cancer	8.35e-05	0.0017	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	8.3e-05	0.00169	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—bone cancer	8.14e-05	0.00166	CcSEcCtD
Raloxifene—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.09e-05	0.00276	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—ATF1—bone cancer	8.06e-05	0.00275	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	8.02e-05	0.00273	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8e-05	0.00273	CbGpPWpGaD
Raloxifene—Gastrointestinal disorder—Methotrexate—bone cancer	7.98e-05	0.00163	CcSEcCtD
Raloxifene—Infection—Doxorubicin—bone cancer	7.96e-05	0.00162	CcSEcCtD
Raloxifene—HTR2B—GPCR ligand binding—GRM4—bone cancer	7.91e-05	0.0027	CbGpPWpGaD
Raloxifene—Pain—Methotrexate—bone cancer	7.91e-05	0.00161	CcSEcCtD
Raloxifene—CYP19A1—Biological oxidations—CYP3A4—bone cancer	7.91e-05	0.00269	CbGpPWpGaD
Raloxifene—Musculoskeletal discomfort—Epirubicin—bone cancer	7.89e-05	0.00161	CcSEcCtD
Raloxifene—Shock—Doxorubicin—bone cancer	7.88e-05	0.0016	CcSEcCtD
Raloxifene—ESR1—Gene Expression—ZNF77—bone cancer	7.87e-05	0.00268	CbGpPWpGaD
Raloxifene—Nervous system disorder—Doxorubicin—bone cancer	7.85e-05	0.0016	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	7.85e-05	0.00268	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	7.84e-05	0.00267	CbGpPWpGaD
Raloxifene—Thrombocytopenia—Doxorubicin—bone cancer	7.84e-05	0.0016	CcSEcCtD
Raloxifene—Insomnia—Epirubicin—bone cancer	7.83e-05	0.00159	CcSEcCtD
Raloxifene—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	7.8e-05	0.00266	CbGpPWpGaD
Raloxifene—Skin disorder—Doxorubicin—bone cancer	7.78e-05	0.00158	CcSEcCtD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	7.75e-05	0.00264	CbGpPWpGaD
Raloxifene—Hyperhidrosis—Doxorubicin—bone cancer	7.74e-05	0.00158	CcSEcCtD
Raloxifene—ESR2—Gene Expression—FUS—bone cancer	7.62e-05	0.0026	CbGpPWpGaD
Raloxifene—Dyspepsia—Epirubicin—bone cancer	7.62e-05	0.00155	CcSEcCtD
Raloxifene—AOX1—Metabolism—NT5C3A—bone cancer	7.59e-05	0.00259	CbGpPWpGaD
Raloxifene—Gastrointestinal pain—Methotrexate—bone cancer	7.56e-05	0.00154	CcSEcCtD
Raloxifene—HTR6—GPCR ligand binding—GRM1—bone cancer	7.52e-05	0.00256	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	7.51e-05	0.00256	CbGpPWpGaD
Raloxifene—Gastrointestinal disorder—Epirubicin—bone cancer	7.47e-05	0.00152	CcSEcCtD
Raloxifene—Pain—Epirubicin—bone cancer	7.4e-05	0.00151	CcSEcCtD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	7.34e-05	0.0025	CbGpPWpGaD
Raloxifene—Abdominal pain—Methotrexate—bone cancer	7.31e-05	0.00149	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—bone cancer	7.31e-05	0.00149	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—bone cancer	7.3e-05	0.00149	CcSEcCtD
Raloxifene—Insomnia—Doxorubicin—bone cancer	7.24e-05	0.00147	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.15e-05	0.00244	CbGpPWpGaD
Raloxifene—Gastrointestinal pain—Epirubicin—bone cancer	7.08e-05	0.00144	CcSEcCtD
Raloxifene—Dyspepsia—Doxorubicin—bone cancer	7.05e-05	0.00144	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—bone cancer	6.91e-05	0.00141	CcSEcCtD
Raloxifene—HTR2B—GPCR ligand binding—GRM1—bone cancer	6.86e-05	0.00234	CbGpPWpGaD
Raloxifene—Pain—Doxorubicin—bone cancer	6.85e-05	0.00139	CcSEcCtD
Raloxifene—Body temperature increased—Epirubicin—bone cancer	6.84e-05	0.00139	CcSEcCtD
Raloxifene—Abdominal pain—Epirubicin—bone cancer	6.84e-05	0.00139	CcSEcCtD
Raloxifene—CYP19A1—Biological oxidations—GSTP1—bone cancer	6.76e-05	0.0023	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	6.72e-05	0.00229	CbGpPWpGaD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	6.67e-05	0.00227	CbGpPWpGaD
Raloxifene—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	6.67e-05	0.00227	CbGpPWpGaD
Raloxifene—ESR1—ATF-2 transcription factor network—JUN—bone cancer	6.66e-05	0.00227	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	6.57e-05	0.00224	CbGpPWpGaD
Raloxifene—Gastrointestinal pain—Doxorubicin—bone cancer	6.55e-05	0.00133	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6.51e-05	0.00222	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	6.42e-05	0.00219	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.39e-05	0.00218	CbGpPWpGaD
Raloxifene—Abdominal pain—Doxorubicin—bone cancer	6.33e-05	0.00129	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—bone cancer	6.33e-05	0.00129	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—bone cancer	6.33e-05	0.00129	CcSEcCtD
Raloxifene—ESR1—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	6.24e-05	0.00213	CbGpPWpGaD
Raloxifene—Dizziness—Methotrexate—bone cancer	6.12e-05	0.00125	CcSEcCtD
Raloxifene—ESR2—SIDS Susceptibility Pathways—JUN—bone cancer	6.06e-05	0.00207	CbGpPWpGaD
Raloxifene—EBP—Metabolism—ENO2—bone cancer	6e-05	0.00205	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—JUN—bone cancer	5.94e-05	0.00202	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.93e-05	0.00202	CbGpPWpGaD
Raloxifene—Diarrhoea—Epirubicin—bone cancer	5.92e-05	0.00121	CcSEcCtD
Raloxifene—Vomiting—Methotrexate—bone cancer	5.88e-05	0.0012	CcSEcCtD
Raloxifene—Rash—Methotrexate—bone cancer	5.83e-05	0.00119	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—bone cancer	5.83e-05	0.00119	CcSEcCtD
Raloxifene—ESR1—AP-1 transcription factor network—JUN—bone cancer	5.81e-05	0.00198	CbGpPWpGaD
Raloxifene—Headache—Methotrexate—bone cancer	5.79e-05	0.00118	CcSEcCtD
Raloxifene—Dizziness—Epirubicin—bone cancer	5.72e-05	0.00117	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.72e-05	0.00195	CbGpPWpGaD
Raloxifene—ESR1—LKB1 signaling events—TP53—bone cancer	5.66e-05	0.00193	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—MMP9—bone cancer	5.65e-05	0.00192	CbGpPWpGaD
Raloxifene—EBP—Metabolism—DHFR—bone cancer	5.57e-05	0.0019	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—NR1I2—bone cancer	5.54e-05	0.00189	CbGpPWpGaD
Raloxifene—Vomiting—Epirubicin—bone cancer	5.5e-05	0.00112	CcSEcCtD
Raloxifene—Nausea—Methotrexate—bone cancer	5.49e-05	0.00112	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—bone cancer	5.48e-05	0.00112	CcSEcCtD
Raloxifene—Rash—Epirubicin—bone cancer	5.46e-05	0.00111	CcSEcCtD
Raloxifene—Dermatitis—Epirubicin—bone cancer	5.45e-05	0.00111	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.44e-05	0.00185	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	5.44e-05	0.00185	CbGpPWpGaD
Raloxifene—Headache—Epirubicin—bone cancer	5.42e-05	0.0011	CcSEcCtD
Raloxifene—HTR6—GPCR ligand binding—SMO—bone cancer	5.3e-05	0.0018	CbGpPWpGaD
Raloxifene—Dizziness—Doxorubicin—bone cancer	5.3e-05	0.00108	CcSEcCtD
Raloxifene—ESR2—Gene Expression—NR1I2—bone cancer	5.29e-05	0.0018	CbGpPWpGaD
Raloxifene—EBP—Metabolism—GNA11—bone cancer	5.21e-05	0.00177	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	5.17e-05	0.00176	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.16e-05	0.00176	CbGpPWpGaD
Raloxifene—Nausea—Epirubicin—bone cancer	5.14e-05	0.00105	CcSEcCtD
Raloxifene—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	5.12e-05	0.00174	CbGpPWpGaD
Raloxifene—Vomiting—Doxorubicin—bone cancer	5.09e-05	0.00104	CcSEcCtD
Raloxifene—CYP2B6—Biological oxidations—CYP3A4—bone cancer	5.08e-05	0.00173	CbGpPWpGaD
Raloxifene—Rash—Doxorubicin—bone cancer	5.05e-05	0.00103	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—bone cancer	5.04e-05	0.00103	CcSEcCtD
Raloxifene—Headache—Doxorubicin—bone cancer	5.02e-05	0.00102	CcSEcCtD
Raloxifene—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	5.01e-05	0.00171	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—RGS1—bone cancer	4.9e-05	0.00167	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—GRM4—bone cancer	4.9e-05	0.00167	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CDK4—bone cancer	4.87e-05	0.00166	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—SMO—bone cancer	4.83e-05	0.00165	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	4.81e-05	0.00164	CbGpPWpGaD
Raloxifene—Nausea—Doxorubicin—bone cancer	4.76e-05	0.000969	CcSEcCtD
Raloxifene—CYP19A1—Metabolism—NDUFA12—bone cancer	4.74e-05	0.00162	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	4.73e-05	0.00161	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CYP3A4—bone cancer	4.72e-05	0.00161	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.7e-05	0.0016	CbGpPWpGaD
Raloxifene—ESR1—Regulation of Telomerase—EGFR—bone cancer	4.67e-05	0.00159	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—KIT—bone cancer	4.56e-05	0.00155	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—GRM4—bone cancer	4.47e-05	0.00152	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—RGS1—bone cancer	4.47e-05	0.00152	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—GRM4—bone cancer	4.45e-05	0.00152	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—RGS1—bone cancer	4.45e-05	0.00152	CbGpPWpGaD
Raloxifene—CYP2B6—Biological oxidations—GSTP1—bone cancer	4.34e-05	0.00148	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—BRAF—bone cancer	4.31e-05	0.00147	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—CYP3A4—bone cancer	4.3e-05	0.00147	CbGpPWpGaD
Raloxifene—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	4.28e-05	0.00146	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—GRM1—bone cancer	4.25e-05	0.00145	CbGpPWpGaD
Raloxifene—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	4.24e-05	0.00144	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—RB1—bone cancer	4.24e-05	0.00144	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—GRM4—bone cancer	4.06e-05	0.00138	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—RGS1—bone cancer	4.06e-05	0.00138	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.05e-05	0.00138	CbGpPWpGaD
Raloxifene—EBP—Metabolism—GSTP1—bone cancer	4.04e-05	0.00138	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.04e-05	0.00138	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	4.03e-05	0.00137	CbGpPWpGaD
Raloxifene—AOX1—Disease—ENO2—bone cancer	3.97e-05	0.00135	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—NT5C3A—bone cancer	3.93e-05	0.00134	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—EIF2S1—bone cancer	3.9e-05	0.00133	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—GRM1—bone cancer	3.88e-05	0.00132	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—GRM1—bone cancer	3.86e-05	0.00131	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—FUS—bone cancer	3.84e-05	0.00131	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—TP53—bone cancer	3.83e-05	0.00131	CbGpPWpGaD
Raloxifene—AOX1—Disease—DHFR—bone cancer	3.69e-05	0.00126	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—GSTP1—bone cancer	3.68e-05	0.00125	CbGpPWpGaD
Raloxifene—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	3.63e-05	0.00124	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—MDM2—bone cancer	3.61e-05	0.00123	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—MDM2—bone cancer	3.59e-05	0.00122	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—GRM1—bone cancer	3.52e-05	0.0012	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	3.51e-05	0.00119	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.4e-05	0.00116	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—EZH2—bone cancer	3.39e-05	0.00116	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—ENO2—bone cancer	3.33e-05	0.00113	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—JUN—bone cancer	3.14e-05	0.00107	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—DHFR—bone cancer	3.09e-05	0.00105	CbGpPWpGaD
Raloxifene—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.05e-05	0.00104	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NDUFA12—bone cancer	3.04e-05	0.00104	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.99e-05	0.00102	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.88e-05	0.000983	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—GNA11—bone cancer	2.88e-05	0.000983	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	2.76e-05	0.000939	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—GNA11—bone cancer	2.74e-05	0.000933	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—SMO—bone cancer	2.72e-05	0.000926	CbGpPWpGaD
Raloxifene—AOX1—Disease—TGFBR2—bone cancer	2.67e-05	0.00091	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—NR1I2—bone cancer	2.67e-05	0.000908	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GRM4—bone cancer	2.63e-05	0.000896	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RGS1—bone cancer	2.63e-05	0.000896	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CYP3A4—bone cancer	2.61e-05	0.000891	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.6e-05	0.000886	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NDUFA12—bone cancer	2.58e-05	0.000878	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—NT5C3A—bone cancer	2.52e-05	0.00086	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—GNA11—bone cancer	2.5e-05	0.000851	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—GNA11—bone cancer	2.49e-05	0.000847	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—IL3—bone cancer	2.48e-05	0.000846	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—SMO—bone cancer	2.48e-05	0.000845	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—EGFR—bone cancer	2.47e-05	0.000841	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—EGFR—bone cancer	2.45e-05	0.000836	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GRM4—bone cancer	2.4e-05	0.000818	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RGS1—bone cancer	2.4e-05	0.000818	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	2.31e-05	0.000789	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GRM1—bone cancer	2.28e-05	0.000777	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—GNA11—bone cancer	2.27e-05	0.000773	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—IL3—bone cancer	2.27e-05	0.000772	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—IL3—bone cancer	2.25e-05	0.000768	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—GSTP1—bone cancer	2.24e-05	0.000762	CbGpPWpGaD
Raloxifene—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.23e-05	0.000761	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—NT5C3A—bone cancer	2.14e-05	0.000728	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTGS2—bone cancer	2.09e-05	0.000713	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GRM1—bone cancer	2.08e-05	0.000709	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—bone cancer	2.07e-05	0.000706	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—IL3—bone cancer	2.06e-05	0.000701	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.04e-05	0.000697	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RGS1—bone cancer	2e-05	0.000681	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GRM4—bone cancer	2e-05	0.000681	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.97e-05	0.000673	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—EIF2S1—bone cancer	1.97e-05	0.000671	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.95e-05	0.000663	CbGpPWpGaD
Raloxifene—AOX1—Disease—KIT—bone cancer	1.82e-05	0.000621	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GRM1—bone cancer	1.73e-05	0.00059	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ENO2—bone cancer	1.72e-05	0.000586	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.72e-05	0.000585	CbGpPWpGaD
Raloxifene—AOX1—Disease—BRAF—bone cancer	1.71e-05	0.000584	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—EZH2—bone cancer	1.71e-05	0.000583	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SMO—bone cancer	1.61e-05	0.000547	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—DHFR—bone cancer	1.6e-05	0.000544	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GNA11—bone cancer	1.49e-05	0.000508	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GNA11—bone cancer	1.47e-05	0.0005	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SMO—bone cancer	1.47e-05	0.000499	CbGpPWpGaD
Raloxifene—AOX1—Disease—MDM2—bone cancer	1.44e-05	0.000489	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTGS2—bone cancer	1.38e-05	0.000471	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NDUFA12—bone cancer	1.38e-05	0.000471	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ATF1—bone cancer	1.37e-05	0.000465	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CYP3A4—bone cancer	1.35e-05	0.000461	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.35e-05	0.000458	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GNA11—bone cancer	1.34e-05	0.000457	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IL3—bone cancer	1.33e-05	0.000454	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ATF1—bone cancer	1.25e-05	0.000425	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SMO—bone cancer	1.22e-05	0.000416	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IL3—bone cancer	1.22e-05	0.000414	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—bone cancer	1.16e-05	0.000395	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTP1—bone cancer	1.16e-05	0.000394	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—NT5C3A—bone cancer	1.15e-05	0.000391	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TGFBR2—bone cancer	1.14e-05	0.000388	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GNA11—bone cancer	1.12e-05	0.000381	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ENO2—bone cancer	1.1e-05	0.000376	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1R—bone cancer	1.07e-05	0.000365	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TGFBR2—bone cancer	1.04e-05	0.000354	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ATF1—bone cancer	1.04e-05	0.000354	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—DHFR—bone cancer	1.02e-05	0.000349	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IL3—bone cancer	1.01e-05	0.000345	CbGpPWpGaD
Raloxifene—AOX1—Disease—EGFR—bone cancer	9.81e-06	0.000334	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1R—bone cancer	9.78e-06	0.000333	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GNA11—bone cancer	9.58e-06	0.000326	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ENO2—bone cancer	9.35e-06	0.000319	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CYP3A4—bone cancer	8.68e-06	0.000296	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—DHFR—bone cancer	8.68e-06	0.000296	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TGFBR2—bone cancer	8.66e-06	0.000295	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1R—bone cancer	8.15e-06	0.000278	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GNA11—bone cancer	8.11e-06	0.000276	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KIT—bone cancer	7.77e-06	0.000265	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTP1—bone cancer	7.43e-06	0.000253	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CYP3A4—bone cancer	7.35e-06	0.000251	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.31e-06	0.000249	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—BRAF—bone cancer	7.3e-06	0.000249	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIT—bone cancer	7.09e-06	0.000242	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—EGFR—bone cancer	7.08e-06	0.000241	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—BRAF—bone cancer	6.67e-06	0.000227	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—EGFR—bone cancer	6.46e-06	0.00022	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTP1—bone cancer	6.29e-06	0.000214	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MDM2—bone cancer	6.12e-06	0.000209	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—bone cancer	5.99e-06	0.000204	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIT—bone cancer	5.91e-06	0.000201	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MDM2—bone cancer	5.59e-06	0.00019	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—BRAF—bone cancer	5.55e-06	0.000189	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—JUN—bone cancer	5.32e-06	0.000181	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—bone cancer	5.17e-06	0.000176	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ENO2—bone cancer	5.02e-06	0.000171	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—JUN—bone cancer	4.85e-06	0.000165	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—bone cancer	4.72e-06	0.000161	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—DHFR—bone cancer	4.66e-06	0.000159	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MDM2—bone cancer	4.65e-06	0.000159	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GNA11—bone cancer	4.35e-06	0.000148	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—EGFR—bone cancer	4.18e-06	0.000142	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—JUN—bone cancer	4.04e-06	0.000138	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—bone cancer	3.93e-06	0.000134	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—bone cancer	3.85e-06	0.000131	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—EGFR—bone cancer	3.82e-06	0.00013	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—bone cancer	3.51e-06	0.00012	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTP1—bone cancer	3.38e-06	0.000115	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—bone cancer	3.26e-06	0.000111	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—bone cancer	3.2e-06	0.000109	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—EGFR—bone cancer	3.18e-06	0.000108	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—bone cancer	2.67e-06	9.1e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—bone cancer	1.75e-06	5.96e-05	CbGpPWpGaD
